Evercore ISI Group analyst Elizabeth Suzuki has maintained an In-Line rating on Humana while raising the price target to $370 from $250. The new target indicates a revised valuation outlook for the healthcare company's stock.

The rating action follows a review of Humana's market position and financial prospects. Despite the higher price target, the In-Line stance suggests the stock is expected to perform in line with the broader market averages.

Humana operates in the healthcare sector, and the adjusted target reflects updated projections regarding its business performance. The analyst's report provides guidance for investors monitoring the company's stock movements.

Humana Inc. has entered into a definitive agreement to divest its minority interest in Gentiva, a provider of end-of-life services, for approximately $900 million. The sale involves a consortium of investors acquiring all or substantially all of Humana's stake in the entity, which operates as the nation's largest provider of hospice and palliative care. Humana intends to use the net proceeds from the transaction for general corporate purposes. The deal is projected to close in the third quarter of 2026, pending regulatory approvals and other customary closing conditions.

The company stated that it does not expect the transaction to have a material impact on its 2026 earnings. Humana's ownership in Gentiva originated from its 2021 acquisition of the remaining interest in Kindred at Home. Following that acquisition, Humana had signaled its intention to divest non-core businesses within the Kindred at Home portfolio, specifically hospice, palliative, and personal health care services.

In 2022, Humana agreed to sell a majority interest in the Hospice and Personal Care divisions of its Kindred at Home subsidiary to Clayton, Dubilier & Rice (CD&R). These divisions were subsequently restructured into a standalone business and rebranded as Gentiva. The company currently provides services through more than 430 locations across 35 states, supported by a network of clinicians and caregivers.

Guggenheim Securities, LLC is acting as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP are acting as legal advisors to Humana.

Transaction Details